You have 9 free searches left this month | for more free features.

Hodgkin lymphoma

Showing 1 - 25 of 5,685

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Brazilian Prospective Hodgkin Lymphoma Registry

Recruiting
  • Hodgkin Lymphoma
  • Hodgkin Disease
    • Rio de Janeiro, Brazil
      Universidade Federal Do Rio de Janeiro
    May 16, 2022

    Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Jinan (CAR-T cells)

    Recruiting
    • Relapsed Non-Hodgkin Lymphoma
    • +2 more
    • CAR-T cells
    • Jinan, Shandong, China
      The Second People's Hospital of Shandong Province
    Jun 14, 2022

    Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Relapsed Classical Hodgkin Lymphoma Trial in Stanford (Magrolimab, Pembrolizumab,

    Recruiting
    • Hodgkin Lymphoma
    • +3 more
    • Stanford, California
      Stanford University
    Jun 21, 2022

    Lymphoma, Non-Hodgkin Lymphoma, B-Cell Trial (BAFF CAR-T)

    Not yet recruiting
    • Lymphoma, Non-Hodgkin Lymphoma, B-Cell
    • BAFF CAR-T
    • (no location specified)
    Aug 16, 2022

    Hodgkin Lymphoma Trial (Tislelizumab, AVD, Radiotherapy)

    Not yet recruiting
    • Hodgkin Lymphoma
    • Tislelizumab, AVD, Radiotherapy
    • (no location specified)
    Nov 15, 2022

    Non-hodgkin Lymphoma, Hodgkin Lymphoma, Lymphoma Trial in Chicago (Radiation - Dose Level 0, Radiation - Dose Level 1, Radiation

    Recruiting
    • Non-hodgkin Lymphoma
    • +2 more
    • Radiation - Dose Level 0
    • +4 more
    • Chicago, Illinois
      University of Chicago
    Dec 3, 2021

    DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

    Not yet recruiting
    • DLBCL - Diffuse Large B Cell Lymphoma
    • +6 more
    • Bridging radiation therapy
    • +2 more
    • (no location specified)
    Nov 11, 2022

    Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult Trial in Leon (Brentuximab Vedotin 50 MG

    Recruiting
    • Hodgkin Lymphoma
    • +2 more
    • Brentuximab Vedotin 50 MG [Adcetris]
    • Leon, Guanajuato, Mexico
      Hospital Regional Alta Especialidad Bajio
    Oct 24, 2022

    Hodgkin Lymphoma Trial (pembrolizumab, brentuximab vedotin)

    Active, not recruiting
    • Hodgkin Lymphoma
    • pembrolizumab
    • brentuximab vedotin
    • (no location specified)
    Aug 18, 2022

    Brentuximab Vedotin in Pediatric Hodgkin Lymphoma

    Not yet recruiting
    • Hodgkin Lymphoma
    • Brentuximab Vedotin
    • (no location specified)
    Jul 28, 2022

    Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Cleveland (Loncastuximab tesirine, Venetoclax)

    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • Refractory Non-Hodgkin Lymphoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cance
    May 20, 2022

    Hodgkin Lymphoma, Lung Cancer Trial in Manchester (Low dose CT thorax)

    Enrolling by invitation
    • Hodgkin Lymphoma
    • Lung Cancer
    • Low dose CT thorax
    • Manchester, United Kingdom
      The Christie NHS Foundation Trust
    Mar 10, 2022

    Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma Trial in United States (CB-010,

    Recruiting
    • Lymphoma, Non-Hodgkin
    • +6 more
    • CB-010
    • +2 more
    • Scottsdale, Arizona
    • +7 more
    Aug 19, 2022

    Hodgkin Lymphoma Trial in New York (Mocetinostat Plus Brentuximab Vedotin)

    Completed
    • Hodgkin Lymphoma
    • Mocetinostat Plus Brentuximab Vedotin
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    May 10, 2022

    Living Conditions After Non-Hodgkin's Lymphoma in France

    Not yet recruiting
    • Non-hodgkin's Lymphoma
    • Data collection
    • Questionnaires
    • Dijon, France
      Chu Dijon Bourgogne
    Oct 13, 2022

    Immunogenicity of COVID-19 Vaccinations in Autologous HSCT

    Not yet recruiting
    • COVID-19
    • +2 more
      • Cologne, NRW, Germany
        University Hospital of Cologne
      Oct 27, 2022

      Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin

      Completed
      • Adult Lymphocyte Depletion Hodgkin Lymphoma
      • +5 more
      • gemcitabine hydrochloride
      • bendamustine hydrochloride
      • Atlanta, Georgia
      • +1 more
      Oct 21, 2021

      Classical Hodgkin Lymphoma Trial in Cologne (Tislelizumab)

      Not yet recruiting
      • Classical Hodgkin Lymphoma
      • Cologne, Germany
        1st Department of Medicine, Cologne University Hospital
      Aug 5, 2022

      Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

      Active, not recruiting
      • Non Hodgkin Lymphoma
      • Cologne, Germany
      • +1 more
      Mar 2, 2022

      Non-Hodgkin Lymphoma, Hodgkin Lymphoma Trial in Minneapolis (drug, procedure, biological, radiation)

      Recruiting
      • Non-Hodgkin Lymphoma
      • Hodgkin Lymphoma
      • Minneapolis, Minnesota
        Masonic Cancer Center, University of Minnesota
      Jan 3, 2022

      Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Chapel Hill (Nivolumab, Pembrolizumab)

      Recruiting
      • Relapsed Hodgkin Lymphoma
      • Refractory Hodgkin Lymphoma
      • Nivolumab
      • Pembrolizumab
      • Chapel Hill, North Carolina
        Lineberger Comprehensive Cancer Center at University of North Ca
      Jul 22, 2022

      Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin

      Recruiting
      • Hodgkin Lymphoma
        • Naples, Italy
          Federico II University
        Feb 15, 2022

        AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection Trial (Axicabtagene Ciloleucel,

        Not yet recruiting
        • AIDS-Related Diffuse Large B-cell Lymphoma
        • +14 more
        • Axicabtagene Ciloleucel
        • +2 more
        • (no location specified)
        Feb 15, 2022

        Solid Tumor, Non-Hodgkin Lymphoma Trial in Shanghai, Hangzhou (Gentulizumab)

        Recruiting
        • Solid Tumor
        • Non-Hodgkin Lymphoma
        • Shanghai, Shanghai, China
        • +1 more
        Jan 21, 2022

        CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

        Active, not recruiting
        • CD20-positive Non-Hodgkin Lymphoma
        • Rituximab + MG4101
        • Seoul, Korea, Republic of
          Seoul National University Hospital
        Feb 4, 2022